RxDoctor Payments Data

Adam Prawer, MD

Family Medicine · St Petersburg, FLNPI 1841594801

Payments from drug & device makers

$10,429in general payments, 2019–2025

Across 548 payments — averaging $19.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$975
  • AstraZeneca$949
  • Lilly USA, LLC$730
  • Amgen$628
  • GSK$498
  • plus $5K from 46 others

What the payments were for

  • Food & beverage$10,32999%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,429 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$770,582
Medicare patients
1,449
Services billed
9,488

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban992$706,439
OzempicSemaglutide139$199,440
XareltoRivaroxaban222$182,062
MounjaroTirzepatide105$151,239
JardianceEmpagliflozin162$127,049
Trelegy ElliptaFluticasone/Umeclidin/Vilanter99$108,632
MyrbetriqMirabegron202$101,570
XifaxanRifaximin22$64,303
JanuviaSitagliptin Phosphate107$63,225
NuplazidPimavanserin Tartrate25$61,754
LinzessLinaclotide64$54,115
CreonLipase/Protease/Amylase40$51,000
GemtesaVibegron92$49,068
FarxigaDapagliflozin Propanediol56$47,294
OdefseyEmtricitab/Rilpiviri/Tenof Ala13$46,160

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Lyrica, Nurtec Odt, Retacrit, Paxlovid$396$757,7611,129 claims
Johnson & JohnsonXarelto, Procrit, Invokana$389$224,329276 claims
Novo NordiskOzempic, Rybelsus$975$220,037161 claims
Lilly USA, LLCMounjaro, Trulicity$730$178,939130 claims
AbbVieLinzess, Creon, Vraylar, Synthroid$1,394$154,223300 claims
GSKTrelegy Ellipta, Breo Ellipta$498$130,690127 claims
Boehringer IngelheimJardiance$36$127,049162 claims
Astellas Pharma US IncMyrbetriq$266$101,570202 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$949$95,449113 claims
MerckJanuvia, Belsomra$36$75,048134 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$251$64,30322 claims
Sumitomo Pharma America, Inc.Gemtesa$495$49,06892 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in St Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →